Toggle

A drug, zanubrutinib, in combination with R-CHOP standard chemotherapy (chemo), to treat diffuse large B-cell lymphoma (DLBCL) with CD5, CD79B, L265P, MYD88 or NOTCH1 mutation

Print

18 and older

Phase 2

1 Location

NCT06846463

Clinical Trial Goal


To find out if zanubrutinib in combination with R-CHOP standard chemo, is safe and works well to treat DLBCL with CD5, CD79B, L265P, MYD88 or NOTCH1 mutation

You may be able to join this trial if you:


  • Are 18 years old or older 
  • Have DLBCL with one of the following mutations (your doctor can tell you this):
    • CD5
    • CD79B
    • L265P
    • MYD88
    • NOTCH1
  • Do not have high grade B-cell lymphoma with any of the following rearrangements (your doctor can tell you this):
    • BCL2
    • BCL6
    • MYC
  • Do not have lymphoma in your brain or spinal cord
  • Agree to have other standard tests done to see if you can be in the clinical trial 

Trial Details


Cyclophosphamide, doxorubicin and vincristine are chemotherapy (chemo) drugs that block the growth of cancer cells.
Prednisone
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
Zanubrutinib is a small molecule inhibitor that blocks BTK in certain cells.

You’ll get:
  • Cyclophosphamide – The dose you'll get depends on when you start the trial and how safe it has been
  • Doxorubicin – The dose you'll get depends on when you start the trial and how safe it has been
  •  Prednisone– The dose you'll get depends on when you start the trial and how safe it has been
  • Rituximab – The dose you'll get depends on when you start the trial and how safe it has been
  • Vincristine – The dose you'll get depends on when you start the trial and how safe it has been
  • Zanubrutinib – A pill that you take by mouth up to 2 times each day

You may continue treatment for up to about 6 months. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years. 

The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using zanubrutinib in this way to treat DLBCL with D5, CD79B, L265P, MYD88 or NOTCH1 mutation is new and unproven. 

Contacts


Massey IIT Research Operations, 804-628-6430, masseyepd@vcu.edu

Locations


Virginia Commonwealth UniversityRECRUITING

Richmond, Virginia
Massey Heme Malig Team, 804-628-6430, MasseyHemMlg@vcu.edu

ClinicalTrials.gov record


NCT06846463. First posted on 2/26/25

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator

1-888-814-8610
contact@ctsearchsupport.org